NCT05206305 · ACTIVE NOT RECRUITING
Sensory-Evoked Cortical Gamma Oscillation
This trial tests a device called GammaSense, which uses flickering light and sound at 40 Hz to stimulate specific brainwave patterns in people already diagnosed with Alzheimer's disease. Researchers are measuring whether this stimulation changes how the brain processes sensory information and whether it affects cognitive function, tracked with EEG brain recordings. This is a Phase NA feasibility-style study, meaning it is exploring whether the approach shows enough signal to study further.
You may qualify if
- Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
- Fluent and literate in English language
- Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
- Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
You're excluded if
- Not fluent and literate in English
- Severe dementia
- Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
- Cardiac pacemakers or any other implants that may not be compatible with MRI
- Cognitively impaired to the point the patient is unable to consent for themselves
- Claustrophobic to the point that medication is required
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-04